ribociclib + camizestrant

**Ribociclib + camizestrant** is an investigational oral combination regimen composed of ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and camizestrant (AZD9833), a next-generation oral selective estrogen receptor degrader (SERD). Ribociclib acts by inhibiting CDK4/6, halting cell cycle progression and proliferation in hormone receptor-positive breast cancer cells. Camizestrant binds, antagonizes, and induces degradation of the estrogen receptor (ER), overcoming resistance mechanisms often seen with traditional hormonal therapies. This combination is being evaluated primarily in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, including those with ESR1 mutations and prior endocrine or CDK4/6 inhibitor therapy[1][3][4][6].

Brand names

Kisqali

Other names

ribociclib + camizestrant